What Rein Therapeutics, Inc. does.

We are a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI‑01 for an undetermined period of time and are prioritizing LTI‑03. Our pipeline includes:

• LTI-03, a peptide, for which we conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, or IPF, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling;

• LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and

Revenue and profit, by fiscal year.

More on RNTX.

• Rein Therapeutics, Inc. summary
• Rein Therapeutics, Inc. financial statements
• Rein Therapeutics, Inc. key metrics
• Rein Therapeutics, Inc. health scores and style box
• Rein Therapeutics, Inc. earnings
• Rein Therapeutics, Inc. dividends
• Rein Therapeutics, Inc. valuation
• Rein Therapeutics, Inc. ownership and insiders
• Rein Therapeutics, Inc. peers

Figures from Rein Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.